Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1 clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program that targets aSyn, a protein that has been identified as genetically linked to Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: beta-secretase 1/Tau, a bispecific program targeting the production of amyloid beta and the spreading of Tau. Further, it is developing LF1, a protein to treat neurodegeneration; and DNL788, a small molecule product candidate for the treatment of Alzheimer's disease and ALS. Additionally, the company has various seed program, which are under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., as well as F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, and AbCellera Biologics. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548
Debt
Debt-to-Equity RatioN/A
Current Ratio12.18
Quick Ratio12.17
Price-To-Earnings
Trailing P/E Ratio-3.47
Forward P/E Ratio-17.02
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book3.86
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees130
Outstanding Shares94,810,000
Market Cap$1.85 billion
Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions
What is Denali Therapeutics' stock symbol?
Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."
How were Denali Therapeutics' earnings last quarter?
Denali Therapeutics Inc (NASDAQ:DNLI) announced its quarterly earnings data on Thursday, August, 9th. The company reported ($0.59) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.39. The business earned $1.65 million during the quarter, compared to the consensus estimate of $3 million. View Denali Therapeutics' Earnings History.
When is Denali Therapeutics' next earnings date?
What price target have analysts set for DNLI?
4 Wall Street analysts have issued 12-month target prices for Denali Therapeutics' shares. Their predictions range from $23.00 to $25.00. On average, they expect Denali Therapeutics' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price. View Analyst Price Targets for Denali Therapeutics.
What is the consensus analysts' recommendation for Denali Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Denali Therapeutics.
Who are some of Denali Therapeutics' key competitors?
Some companies that are related to Denali Therapeutics include Ablynx (ABLYF), argenx (ARGX), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Rubius Therapeutics (RUBY), Solid Biosciences (SLDB) and Editas Medicine (EDIT).
Who are Denali Therapeutics' key executives?
Denali Therapeutics' management team includes the folowing people:
- Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 42)
- Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 45)
- Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 58)
- Mr. Steve E. Krognes, CFO, Principal Accounting Officer & Treasurer (Age 49)
- Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 45)
When did Denali Therapeutics IPO?
(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.
Has Denali Therapeutics been receiving favorable news coverage?
Headlines about DNLI stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Denali Therapeutics earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave news articles about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Denali Therapeutics.
Who are Denali Therapeutics' major shareholders?
Denali Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (8.48%), FMR LLC (8.51%), Baillie Gifford & Co. (5.66%), BlackRock Inc. (1.19%), Jasper Ridge Partners L.P. (0.30%) and Northern Trust Corp (0.20%). Company insiders that own Denali Therapeutics stock include Douglas K Bratton and Ryan J Watts. View Institutional Ownership Trends for Denali Therapeutics.
Which major investors are selling Denali Therapeutics stock?
Which major investors are buying Denali Therapeutics stock?
DNLI stock was purchased by a variety of institutional investors in the last quarter, including Jasper Ridge Partners L.P., Millennium Management LLC, Baillie Gifford & Co., BlackRock Inc., Citadel Advisors LLC, Swiss National Bank, Northern Trust Corp and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Denali Therapeutics.
How do I buy shares of Denali Therapeutics?
Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Denali Therapeutics' stock price today?
One share of DNLI stock can currently be purchased for approximately $20.42.
How big of a company is Denali Therapeutics?
Denali Therapeutics has a market capitalization of $1.85 billion. The company earns $-88,180,000.00 in net income (profit) each year or ($5.89) on an earnings per share basis. Denali Therapeutics employs 130 workers across the globe.
How can I contact Denali Therapeutics?
Denali Therapeutics' mailing address is 151 OYSTER POINT BLVD. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.
MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
